Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM -7.64%36 Forward Dividend Yield % is 0.00% as of Aug. 10, 2026. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 149 Biotechnology companies, BioStem Technologies ranks worse than 671140.27% on this metric.
As of today (2026-08-10), the Forward Annual Dividend Yield of BioStem Technologies is 0.00%.
As of today (2026-08-10), the Trailing Annual Dividend Yield of BioStem Technologies is 0.00%.
BSEM's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.28 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BioStem Technologies Forward Dividend Yield % Related Terms
BSEM vs RNTX, SPRO, ACRV: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, BioStem Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
BioStem Technologies (BSEM) has a Forward Dividend Yield % of 0.00% as of Aug. 10, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #999999 out of 149 companies in the Biotechnology industry.
Is BioStem Technologies' Forward Dividend Yield % too high?
BioStem Technologies' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, BioStem Technologies ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Forward Dividend Yield % compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #999999 out of 149 companies for Forward Dividend Yield %. This places BioStem Technologies in the lower half of its industry. The industry median Forward Dividend Yield % is 1.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.28, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Forward Dividend Yield % is 0.00% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score
Get the complete analysis for BSEM
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
